Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]
Christine Massien, MD [clinicaltrials_resource:03135304e88751b246de1e0e93113d37]Study Director [clinicaltrials_resource:048472fbb2adae9bc1d5f66d477cccba]Antoine Clermont, MD [clinicaltrials_resource:06120eccbcdf2b44d3d2033517f987ac]Jing-dong Ma, MD [clinicaltrials_resource:0946434645a7c3d0c8fdecd7ef5f06c9]Medical Director Neurology, M.D. [clinicaltrials_resource:0aefcc1e9ac90e2a3a0e42e042f32b98]Joëlle Blumberg, MD [clinicaltrials_resource:0b163a8ec01ef385a3441f2d34b735e2]Stefan Lempereur, MD [clinicaltrials_resource:0b354012d1a0eff817d3e3546ca4f5b3]Mehemed Ouzid, MD [clinicaltrials_resource:0cddebecd8915adda45e35dabf8997bd]Phillippe Garnier, MD [clinicaltrials_resource:0dc0272ecae678c4c12b722892492e18]Elena Hernández, BSc. MBA [clinicaltrials_resource:0feb2f7037ef73b92aa00ee218687de9]Bryan Qvick, MD [clinicaltrials_resource:14247bf90a0c07fa3bc46e0c6467f2c4]Ipsen Study Director [clinicaltrials_resource:16f42f43ed2aaa14036bb537976fe2e2]Aurelio Yamada, MD [clinicaltrials_resource:19026f024f9b9fb24bab9cc5cbf35932]Medical Director, Neurology [clinicaltrials_resource:1b24785b2ea5403ec10369f818d0f4ad]UK Medical Director, MD [clinicaltrials_resource:242d5484f23583e64926f923fefbb256]Medical Director Oncology [clinicaltrials_resource:24c0d1dc9fd94e5e23c5bb1ce24d3f8b]Eugène Vissers, MD [clinicaltrials_resource:251381cbf90a7c0f983021a010a801d5]Luana Ionascu [clinicaltrials_resource:281cb670f52733f25ba63a0c6f7a428f]Pascal Birman, MD [clinicaltrials_resource:2b599717fa46c28145701a467fae0eec]Philippe Picaur [clinicaltrials_resource:2edb0504acbee204237bc7c9ab5a786a]Anne Fairey, MD [clinicaltrials_resource:3092b0216ef97e80132b7374f50a458c]Patrick Cabri, M.D. [clinicaltrials_resource:326d3a7c00bd31764c0ee3c48aaa1d99]Sam Vohra [clinicaltrials_resource:32ff715c473f77d8bb0132c36d4bb98b]Jovita Balcaitiene, MD [clinicaltrials_resource:378e91cd14e07129212f278a3c3f7030]Cécile Merdrignac, MD [clinicaltrials_resource:3bf0e00ebc43c2203ff5d1cd5c92cea6]Pascale Dutailly, MD [clinicaltrials_resource:3dd4050361815b9942bbf443d024c5a6]Benjamin Zakine, MD [clinicaltrials_resource:4726c78aea3136c0a1a93dfd71a0b07d]Elena Hernandez [clinicaltrials_resource:48b9ee934c48ea8b69e2f8c1a62caf8a]Marcus V. Chio Ming Coelho de Sa, MD [clinicaltrials_resource:4cd05139d5b6fc24aa90bae7922d262d]Mónica de Abadal, MD [clinicaltrials_resource:4d7813e19bf02dab63ec01b6ddd6b9e8]Savary Om, M.D. [clinicaltrials_resource:52a41529c727cd81373bb4fd2920b907]Hélène Mathiex-Fortunet, M.D. [clinicaltrials_resource:542203e336946caab89e0e97a7f49d6b]UK Medical Director [clinicaltrials_resource:551892fc77354d668caf6f0ff3202a81]Agnieszka Sobczyńska, M.D. [clinicaltrials_resource:552803db42cd363e25a907b164c62fd6]Guillermo De la Cruz Sugrañas, M.D. [clinicaltrials_resource:55f2416d7839debe1fceda43f2653e47]Medical Director Uro-Oncology [clinicaltrials_resource:5816d2827283435d4609dbe612b79846]Gino Ciotti, MD [clinicaltrials_resource:5c073471b1eae655fe9f83b25dd02bcb]Paola Mazzanti, MD [clinicaltrials_resource:5c41a83fa6fbc32ec8c179be3da8c730]Ipsen Study Director [clinicaltrials_resource:5daff475ec8a1a7c38828aabbca1ffd3]Viveka Aberg [clinicaltrials_resource:62affec1a33877c56a632b445c177658]
affiliation [clinicaltrials_vocabulary:affiliation]
collaborator [clinicaltrials_vocabulary:collaborator]
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) [clinicaltrials:NCT00080015]Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome [clinicaltrials:NCT00092287]clinicaltrials:NCT00125164clinicaltrials:NCT00125190Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome [clinicaltrials:NCT00134810]Somatuline Autogel: Acromegaly Self/Partner Injection Study [clinicaltrials:NCT00149188]Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome [clinicaltrials:NCT00149240]Post Marketing Surveillance Study of Dysport [clinicaltrials:NCT00210431]Efficacy Study of Dysport® in the Treatment of Anal Fissure. [clinicaltrials:NCT00210444]Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis [clinicaltrials:NCT00216372]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm [clinicaltrials:NCT00216411]Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm [clinicaltrials:NCT00234507]A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide [clinicaltrials:NCT00234520]Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq [clinicaltrials:NCT00234533]Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity [clinicaltrials:NCT00234546]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. [clinicaltrials:NCT00246142]Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain [clinicaltrials:NCT00246155]Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) [clinicaltrials:NCT00247559]To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence. [clinicaltrials:NCT00255372]clinicaltrials:NCT00257660Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm [clinicaltrials:NCT00276315]Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults [clinicaltrials:NCT00276328]Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis [clinicaltrials:NCT00276341]Study of Long-Term Use of Forlax® in Elderly Patients With Chronic Constipation [clinicaltrials:NCT00276354]A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke [clinicaltrials:NCT00276380]A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints [clinicaltrials:NCT00276510]clinicaltrials:NCT00288509Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment [clinicaltrials:NCT00288522]Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis [clinicaltrials:NCT00301665]Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours [clinicaltrials:NCT00326469]clinicaltrials:NCT00330668Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children [clinicaltrials:NCT00352716]Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children [clinicaltrials:NCT00352989]clinicaltrials:NCT00353496Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer [clinicaltrials:NCT00415246]Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) [clinicaltrials:NCT00444639]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Pascale Dutailly, Ipsen [clinicaltrials_resource:09093421c16535f588f1dfa079324641]Axel Magis MD, Ipsen [clinicaltrials_resource:25e467da35c9cdd63a739ea12660628e]Joelle Blumberg, Ipsen [clinicaltrials_resource:3d66afca4b64259b051d18d424d49d3a]Pascale Dutailly MD, Ipsen [clinicaltrials_resource:4e2dc20e4384389d5e4cb6b54389d544]Eric Chetaille MD, Ipsen [clinicaltrials_resource:52dc308c9c571a34e3746f4633883db1]Dr Anne Kornowski, Ipsen [clinicaltrials_resource:6104ec8c7a34455d60a5cc13ca4cff7a]Eva Pineda, Ipsen [clinicaltrials_resource:618991829f9efd9f014e8da805c3deef]Jean-Loic Robin, Ipsen [clinicaltrials_resource:639ccc11707f5189b7114eb53eaa4c6f]Sandrine Lewin, Ipsen [clinicaltrials_resource:6435f3b8eeb6e77f063867af6e2ca141]Ipsen Study Director, Ipsen [clinicaltrials_resource:67f407d61dc03ee80fa2e1e3ce310549]Benjamin Zakine, Ipsen [clinicaltrials_resource:82d0fe2dab38930afefa7b0818204ec9]Patrick Cabri, Ipsen [clinicaltrials_resource:bd8e3c5251be7cc3b4c44b4cba580d28]Robin Kingswell, Ipsen [clinicaltrials_resource:be499630c9836bb20ef77e609a561951]Bert Van Eijk, Ipsen [clinicaltrials_resource:d2232b789511117b4927b06354add8ef]Stefan Lempereur, Ipsen [clinicaltrials_resource:dc3917e6a373d38cdc035c2f6544dca3]Senior Vice President, Clinical Development and Medical Affairs, Ipsen [clinicaltrials_resource:e38a0f5672c5ef9de578c890b5fa2ff0]
organization [clinicaltrials_vocabulary:organization]
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) [clinicaltrials:NCT00080015]Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome [clinicaltrials:NCT00092287]clinicaltrials:NCT00125164clinicaltrials:NCT00125190Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome [clinicaltrials:NCT00134810]Somatuline Autogel: Acromegaly Self/Partner Injection Study [clinicaltrials:NCT00149188]Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome [clinicaltrials:NCT00149240]Post Marketing Surveillance Study of Dysport [clinicaltrials:NCT00210431]Efficacy Study of Dysport® in the Treatment of Anal Fissure. [clinicaltrials:NCT00210444]Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients [clinicaltrials:NCT00210457]Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis [clinicaltrials:NCT00216372]Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR [clinicaltrials:NCT00216398]Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm [clinicaltrials:NCT00216411]Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm [clinicaltrials:NCT00234507]A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide [clinicaltrials:NCT00234520]Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq [clinicaltrials:NCT00234533]Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity [clinicaltrials:NCT00234546]Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly [clinicaltrials:NCT00234572]A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. [clinicaltrials:NCT00246142]Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain [clinicaltrials:NCT00246155]Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) [clinicaltrials:NCT00247559]To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence. [clinicaltrials:NCT00255372]clinicaltrials:NCT00257660Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm [clinicaltrials:NCT00276315]Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults [clinicaltrials:NCT00276328]Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis [clinicaltrials:NCT00276341]Study of Long-Term Use of Forlax® in Elderly Patients With Chronic Constipation [clinicaltrials:NCT00276354]A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke [clinicaltrials:NCT00276380]A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints [clinicaltrials:NCT00276510]clinicaltrials:NCT00288509Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment [clinicaltrials:NCT00288522]Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis [clinicaltrials:NCT00301665]Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours [clinicaltrials:NCT00326469]clinicaltrials:NCT00330668Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children [clinicaltrials:NCT00352716]Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children [clinicaltrials:NCT00352989]clinicaltrials:NCT00353496Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [clinicaltrials:NCT00383708]Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer [clinicaltrials:NCT00415246]Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) [clinicaltrials:NCT00444639]
source [clinicaltrials_vocabulary:source]
Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]
Bio2RDF identifier
72e24e8f01584e350155390bbce36547
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:72e24e8f01584e350155390bbce36547
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:72e24e8f01584e350155390bbce36547
title
Ipsen
@en
type
label
Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]
@en